GlassScriptPhysician profile
Diana Whitehead
NPI 1356661169
$325,510.06
in general payments reported to CMS, 2019-2025
39 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $14K · 2021: $14K · 2022: $25K · 2023: $74K · 2024: $78K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $179K · Consulting Fee: $38K · Travel and Lodging: $28K · Food and Beverage: $11K · Education: $25.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $178,785.36 |
| Consulting Fee | $37,605.00 |
| Travel and Lodging | $28,225.81 |
| Food and Beverage | $11,391.40 |
| Education | $25.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $206,502.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $102,388.43 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| E.R. Squibb & Sons, L.L.C. | $10,980.00 | 2023 | Zeposia |
| Celgene Corporation | $1,309.48 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,161.10 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $594.32 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.66 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $366.51 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $208.18 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $183.31 | 2023-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $148.96 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $133.69 | 2023-2024 | Ocaliva |
| Lilly USA, LLC | $130.39 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $102.40 | 2024 | Injectafer |
| Amgen INC. | $84.87 | 2023 | Avsola, Amjevita |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.